Main research fields:
Rare tumors
Gastrointestinal stromal tumours (GIST) (www.giststudygroup.it)
Visceral Sarcoma (www.sarcomastudyroup.it)
Next generation sequencing of solid tumors
Biomolecular prognostic factors of solid tumours and new
molecular targets for cancer therapy
Molecular Imaging in Medical Oncology
Clinical trials development according to Good Clinical
Practice
Main Research projects :
- Identification of somatic mutations or other molecular events
in gastrointestinal stromal tumor (GIST) resistant to imatinib
- Integratedgenomic study of KIT/PDGFRA/SDH/RAS pathway wild-type
GIST: identification of a new GIST subtype (quadruple
KIT/PDGFRA/SDH/RAS-P WT)
- Clinical outcome of SDH deficient GIST
- Evaluation of candidate somatic mutations in KIT/PDGFRA WT GIST
identified by deep-sequencing analysis
- Massively parallel genome sequencing of abdominal sarcoma
- Mutational analysis of c-kit and PDGFr-alfa in secondary
resistance to TK inhibitors in GIST patients
- Preclinical development of new drugs in Gastrointestinal
Stromal Tumors (GIST) using molecular imaging tecniques
(small-animal PET with FLT and FDG)”
- In vivo studies for development and radiosynthesis of new
tracers as MICRO-PET biomarkers for molecular imaging of epidermal
growth factor receptor (EGFr)”.
- Molecular detection of epidermal growth factor receptor (EGFr)
in colorectal cancer and normal colorectal mucosa
- Gene expression profiling of liver metastases from colorectal
cancer using microarray Affymnterix platform
- Title: Evaluation of genetic polymorphisms in transport and
metabolism enzymes of TK inhibitors as predictors of treatments
response in GIST patients
The study and the multidisciplinary management of patients with
rare tumors, such as gastrointestinal tumors, sarcoma and rare
tumors, are highly complex. The research
activity includes the diagnosis and treatment of these
tumors with the clinical interpretation of the imaging and
molecular diagnostic test, the application of standard and new
drugs and conduction of clinical trial following the good clinical
practice.
